Daratumumab for kidney disease caused by immune deposits
Treatments studied
Part of Blood & lymphatic, Kidney & urinary clinical trials.
This Phase 2 study tests daratumumab (an immune-targeting medicine) in people with PGNMID, a kidney disease where abnormal immune proteins build up in the kidney filters. It aims to reduce harmful protein in the urine and improve kidney health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- A kidney biopsy at Mayo Clinic must confirm you have PGNMID
- Your urine protein must be high: at least 1000 mg in 24 hours
- Your kidney filtering function must be enough for study safety (creatinine clearance ≥ 20 mL/min/SA)
- You must be able and willing to sign informed consent
- If you can get pregnant: you must use two reliable birth control methods (or continuous sexual abstinence) starting 4 weeks before treatment and for 3 months after the last dose
- You must not be planning pregnancy, and you must follow study rules for pregnancy testing during screening and right before dosing
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if daratumumab can help people with a kidney condition called MGRS, where abnormal proteins damage the kidneys. The goal is to see if the drug can reduce protein in the urine and protect kidney function.
This trial tests a combination of three drugs (daratumumab, bortezomib, cyclophosphamide, and dexamethasone) for people with rare kidney diseases caused by abnormal plasma cells. It aims to see if this treatment can help control the disease and protect kidney function.
This trial tests a combination of four drugs (CyBorD plus daratumumab) to treat kidney damage caused by abnormal proteins (monoclonal gammopathy). It aims to improve kidney function and reduce protein levels.
This Phase 2 trial studies daratumumab (an antibody medicine) for adults whose rare lymph node/immune-related cancers have come back or did not respond to treatment. It may help shrink disease and improve symptoms, including for people living with HIV when their virus is well controlled.
This trial tests whether daratumumab can help treat a type of rejection that happens more than a year after a kidney transplant. It may be an option for people who have biopsy-proven antibody-mediated rejection and new donor-specific antibodies.
This trial tests a combination of four medications (daratumumab, bortezomib, cyclophosphamide, and dexamethasone) for people with monoclonal immunoglobulin deposition disease (MIDD), a condition where abnormal proteins build up in organs. The goal is to see if this treatment can help without prior harsh therapies.
Hear when a new Proliferative Glomerulonephritis With Monoclonal IgG Deposits trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.